FIELD: biotechnology.
SUBSTANCE: present invention relates to the use of an antibody against CD134 as a cytotoxic agent for the treatment of HIV infection. The antibody against CD134 is selected from a group consisting of MEDI6469 (9B12), MEDI6383, MEDI0562, Hu106-222 and Hu119-122 (UTMDACC).
EFFECT: invention provides for minimization of side effects, destruction of a virus or a virus-infected cell.
2 cl, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF SUPPRESSION OF HIV-INFECTED MAMMALIAN CELLS AND PROTEIN RECOMBINANT RECEPTOR FOR ITS REALIZATION | 1995 |
|
RU2165703C2 |
| METHOD OF DIRECTION OF CELLULAR IMMUNE RESPONSE AGAINST HIV-INFECTED MAMMALIAN CELL, PROTEIN MEMBRANE-BOUND CHIMERIC RECEPTOR, DNA | 1995 |
|
RU2173167C2 |
| REDIRECTION OF CELLULAR IMMUNITY BY CHIMERIC RECEPTORS | 1996 |
|
RU2167676C2 |
| METHOD OF DIRECTION OF IMMUNE RESPONSE INDUCTION, DNA, VECTOR, METHOD OF TREATMENT | 1992 |
|
RU2161044C2 |
| METHOD FOR STABLE CELL TRANSDUCTION BY VIRAL VECTORS | 2001 |
|
RU2280074C2 |
| PROTEIN CHIMERIC RECEPTOR, DNA ENCODING PROTEIN CHIMERIC RECEPTOR | 1994 |
|
RU2158305C2 |
| COMPOSITIONS AND METHODS USED FOR ASSESSING CYTOTOXICITY OF SINGLE CELLS | 2009 |
|
RU2532228C2 |
| METHODS AND COMPOSITIONS FOR TREATMENT OF PERSISTENT INFECTIONS | 2016 |
|
RU2746383C2 |
| METHOD AND COMPOSITIONS FOR TREATMENT OF PERSISTING INFECTIONS | 2006 |
|
RU2434641C2 |
| IMMUNOGENIC COMPOSITION AND METHOD OF FUSED PROTEIN VACCINE DEVELOPMENT | 2004 |
|
RU2407749C2 |
